John Cashman

Institution Name:

Human BioMolecular Research Institute

Total Awards:

4

Award Value:

$7,403,428

Share

Awards as PI

Program Type	Institution	Grant Title	Award Value
SEED Grant	Human BioMolecular Research Institute	Discovering Potent Molecules with Human ESCs to Treat Heart Disease	$688,274
Early Translational IV	Human BioMolecular Research Institute	Improving Existing Drugs for Long QT Syndrome type 3 (LQT3) by hiPSC Disease-in-Dish Model	$6,361,369
Patent Assistance Fund Awards	Human BioMolecular Research Institute	Intellectual Property for Stem Cell-Related Inventions - HBRI	$50,000
Inception - Discovery Stage Research Projects	Human BioMolecular Research Institute	Human Pancreatic Cancer Stem Cells: Developing a Novel Drug for Cancer Eradication	$303,785
			Total: $7,403,428.00

Publications

Cell Stem Cell 2012 Small Molecule-Mediated TGF-beta Type II Receptor Degradation Promotes Cardiomyogenesis in Embryonic Stem Cells. (PubMed: 22862949)
Bioorg Med Chem 2015 1,5-Disubstituted benzimidazoles that direct cardiomyocyte differentiation from mouse embryonic stem cells. (PubMed: 26278027)
Proc. SPIE 2011 Adaptive optics wide-field microscope corrections using a MEMS DM and Shack-Hartmann wavefront sensor (PubMed: )
Front Physiol 2017 An Automated Platform for Assessment of Congenital and Drug-Induced Arrhythmia with hiPSC-Derived Cardiomyocytes. (PubMed: 29075196)
Am J Cancer Res 2019 Inhibition of invasive pancreatic cancer: restoring cell apoptosis by activating mitochondrial p53. (PubMed: 30906636)
Sci Rep 2020 PAWI-2 overcomes tumor stemness and drug resistance via cell cycle arrest in integrin beta3-KRAS-dependent pancreatic cancer stem cells. (PubMed: 32514015)